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Hisanori Nambu, Narumi Noda, Wenqi Niu, Tomoya Fujiwara, and Takayuki Yakura*[a] 
Abstract: The stereoselective total synthesis of myriocin was 
achieved by using the Du Bois Rh(II)-catalyzed C−H amination of 
sulfamate 6 and a subsequent alkylation. The reaction of sulfamate 
6 with PhI(OAc)2 and MgO in the presence of Rh2(OAc)4 gave 
oxathiazinane N,O-acetal as the sole product in high yield. Alkylation 
of the N,O-acetal using vinylmagnesium bromide in the presence of 
ZnCl2 proceeded stereoselectively to provide an oxathiazinane 
bearing a quaternary chiral center in high yield. This route includes 
the first application of the Du Bois procedure for the construction of a 
quaternary chiral center. 
Myriocin (1) is a complex α,α-disubstituted amino acid natural 
product structurally related to sphingolipids. It was initially 
isolated from the fermentation broth of the thermophilic fungi 
Myriococcus albomyces[1] and Mycelia sterila (Figure 1).[2] In 
1994, it was also found in the culture broth of Isalia sinclairii.[3] 
Notably, myriocin exhibits 10–100 times more potent 
immunosuppressive activity than cyclosporine A[3] and has also 
been shown to have potent inhibitory activity against serine 
palmitoyltransferase (SPT), which is an essential enzyme in the 
biosynthesis of sphingolipids.[4] Its challenging structural motif 
with a quaternary chiral center and three contiguous chiral 
centers and interesting biological activity make myriocin an 
attractive target for total synthesis.[5] In our laboratory, we have 
been exploring the synthesis of sphingosine natural products 
using Rh(II)-catalyzed reactions as key steps.[6] As part of this 
program, we developed a novel strategy for the concise 
synthesis of myriocin and its analogues, such as mycestericins[7]  
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Figure 1. Structure of myriocin (1). 
and sphingofungins,[8] by applying Du Bois’ Rh(II)-catalyzed C–H 
amination–alkylation procedure.[9] Herein, we report the 
stereocontrolled total synthesis of myriocin (1). 
Our retrosynthetic strategy for myriocin (1) is outlined in 
Scheme 1. Because it would provide high flexibility for analogue 
synthesis, introduction of the long side chain at a later stage in 
the synthesis was proposed. This reaction would involve cross 
metathesis of amino alkene 2, which contains all of the 
asymmetric carbons of myriocin with their desired configurations, 
and the known alkene 3.[10] It was anticipated that 2 would be 
accessible from oxathiazinane 4 by ring opening followed by 
stereoselective allylation. The construction of the key quaternary 
chiral center of 4 can be realized stereoselectively by applying of 
Du Bois’ Rh(II)-catalyzed C−H amination reaction[11] of sulfamate 
6, followed by stereoselective alkylation.[9] Although Du Bois’ 
pioneering work has been applied to the synthesis of propargylic 
amine derivatives[9a] and (+)-saxitoxin,[9b,c] there are no reported 
examples of its use for the construction of quaternary chiral 
centers. Sulfamate ester 6 would be prepared from commercially 
available diethyl L-tartrate (7). 
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Scheme 1. Retrosynthetic analysis of myriocin (1). 
Our synthesis commenced from 7, as shown in Scheme 2. 
Conversion of 7 to the known alcohol 8 was conducted 
according to the literature.[12] Reaction of 8 with chlorosulfonyl 
isocyanate, formic acid, and pyridine in dichloromethane 
afforded sulfamate ester 9 in 87% yield.[13] Rhodium(II)-
catalyzed C–H amination of 9 using Du Bois’ conditions[11] 
proceeded stereospecifically to give oxathiazinane N,O-acetal 
10. Thus, treatment of 9 with 4 mol% of dirhodium(II)
tetraacetate, 1.1 equivalents of phenyliodine(III) diacetate, and
2.3 equivalents of magnesium oxide in dichloromethane at room
temperature for 1 h gave the corresponding C–H amination
product 10 in 84% yield. Fortunately, alkylation of 10 worked
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very well with high stereoselectivity to form oxathiazinanes 11 
and 12. Reaction of 10 and 4.2 equivalent of vinylmagnesium 
bromide in the presence of zinc chloride (2.2 eq) in 
dichloromethane at room temperature for 6 h produced 11 as 
the sole product in 86% yield. When ethynylation of 10 was 
performed,[14] a slight modification of the Du Bois’ conditions was 
required; 10 was reacted with trimethylsilylethynylzinc chloride 
generated from 4.2 equivalents of trimethylsilylacetylene, butyl 
lithium (4.0 eq) and zinc chloride (4.2 eq) in the presence of 
boron trifluoride diethyl etherate (4.2 eq) in tetrahydrofuran at 
50 °C for 1 h to afford 12 in 71% yield as the sole product. 
These results demonstrate that Du Bois’ C−H amination–
alkylation procedure was effective for the stereoselective 
construction of the quaternary chiral center. The 
stereoselectivities of the C−H amination–alkylation reaction were 
observed in a similar manner as those reported by Du Bois.[9, 15] 
Thus, the alkylation would proceed through intermediate A,[9c] 
which may be intramolecularly coupled to nucleophiles. 
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Scheme 2. Construction of the quaternary chiral center. 
With the stereoselective construction of the quaternary chiral 
center in 1 accomplished, attention was focused on the 
formation of the three contiguous chiral centers, as illustrated in 
Scheme 3. Considering the yields of 11 and 12 and the 
necessary further conversions, vinyl compound 11 was selected 
for the synthesis of 1. Prior to the opening of the oxathiazinane 
ring, the OH and NH groups were protected. Acetylation of the 
hydroxy group in 11 followed by Boc protection of the amino 
group gave protected oxathiazinane 13 in high yield. However, 
the ring opening of 13 was somewhat troublesome. When 13 
was warmed in acetonitrile–water (11:2) at 50 °C,[9b,c, 11b] 
decomposition was observed. Use of 0.1 M phosphate buffer 
instead of water led to ring-opening and an interesting 1,2-acetyl 
group shift to give secondary alcohol 14 as the major product in 
31% yield and the initially expected primary alcohol 14' in 7% 
yield. As a result of an examination of solvent effects,[16] 
warming of 13 in a tetrahydrofuran-buffer solution (11:2) at 50 °C 
for 24 h was found to afford 14 and 14' in 73% and 23% yields, 
respectively. Longer reaction times led to low yields of the 
desired products due to decomposition; however, treatment of 
purified 14' under the same reaction conditions gave 14 in 80% 
yield. Protection of the secondary OH group with chloroacetyl 
chloride and pyridine gave chloroacetate 15. Reductive 
ozonolysis of 15 resulted in conversion of the vinyl group to a 
hydroxymethyl substituent and chloroacetyl deprotection to form 
diol 16 in 82% yield. After protection of the diol as an acetonide, 
methanolysis of the acetoxy group and subsequent Swern 
oxidation produced aldehyde 17. 
To form the third stereocenter, chelation-controlled allylation 
of 17 was investigated. Reaction of 17 with allylmagnesium 
bromide in THF gave a 1:3.5 mixture of desired 18 and 
undesired 18' in 36% combined yield. The low yield and 
undesired stereoselectivity were addressed using indium 
chemistry.[17] Thus, the treatment of 17 with allylbromide and 
indium metal in the presence of tetrabutylammonium iodide and 
magnesium iodide in N,N-dimethylformamide gave 18 as the 
major product (18:18' = 6.6:1) in 84% yield.[18] The two 
diastereomers were then readily separated by column 
chromatography. 
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Scheme 3. Formation of the three continuous chiral centers. 
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The stage was now set for completion of the synthesis of 
myriocin (1). After protection of the secondary hydroxy 
substituent in 18 as an acetoxy group, the long alkyl chain was 
introduced using Grubbs’ cross metathesis chemistry with the 
known alkene 3[10] and coupling product 20, which has all of the 
carbons of the myriocin skeleton, was obtained in 96% yield. 
Desilylation of the primary silyl ether in 20 and subsequent 
Swern oxidation of the resulting hydroxyl group gave aldehyde 
21. Oxidation of 21 to the corresponding carboxylic acid and 
global deprotection by sequential alkaline and acidic hydrolyses 
produced crude myriocin (1). Since it was difficult to directly 
obtain 1 in high purity, the crude product was acetylated with 
acetic anhydride in pyridine to afford the known γ-lactone 22: 
[α]D18 +55.6 (c=1.0, CHCl3) {lit.[5d] [α]D23 +52.5 (c=0.85, CHCl3)}. 
Finally, saponification of 22 followed by neutralization with 
Amberlite® IRC-86 furnished pure 1. The synthetic compound 1 
was spectroscopically (1H and 13C NMR, and IR) identical to 
natural 1, and its melting point (165–168 °C) and optical rotation 
{[α]D23 +5.6 (c=0.30, DMSO)} were in good agreement with 
literature values for the natural product {mp 164–168 °C,[3] [α]D20 
+6.1 (c=0.26, DMSO)[5d]}. 
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Scheme 4. Synthesis of myriocin (1). 
In summary, the stereoselective synthesis of myriocin was 
achieved, with Rh(II)-catalyzed C−H amination of sulfamate 
followed by stereoselective alkylation and In-mediated 
stereoselective allylation as key steps. This synthesis is the first 
example of the construction of a quaternary chiral center using 
sequential Rh(II)-catalyzed C−H amination/alkylation reactions. 
Since the quaternary chiral center can be easily and 
stereoselectively constructed and the long side chain can be 
introduced at a later stage in the synthesis, the present method 
would provide high flexibility for analogue synthesis. Thus, the 
synthesis of myriocin analogues including mycestericin D and 
sphingofungin E is currently in progress. 
Experimental Section 
Procedure for Rh(II)-catalyzed C−H amination and subsequent 
alkylation 
Rh2(OAc)4 (270 mg, 0.611 mmol), PhI(OAc)2 (5.39 g, 16.7 mmol) and 
MgO (1.41 g, 35.0 mmol) were added to a solution of sulfamate 9 (7.29 g, 
15.2 mmol) in CH2Cl2 (96 mL). After stirring at room temperature for 1 h, 
the reaction mixture was filtered through a pad of Celite. The filter cake 
was rinsed with CH2Cl2, and the combined filtrates were concentrated in 
vacuo. The residue was purified by column chromatography (silica gel, 
10% EtOAc in hexane) to provide 10 (6.11 g, 84%) as a white solid. 
Next, ZnCl2 (0.92 mL, 0.92 mmol) was added dropwise to a solution of 
vinylmagnesium bromide (1.76 mL, 1.0 M in THF, 1.76 mmol) at –78 °C 
under nitrogen, and the resulting mixture was warmed to room 
temperature and stirred for 0.5 h. The reaction mixture was then cooled 
to 0 °C, and a solution of 10 (200 mg, 0.42 mmol) in THF (1.0 mL) was 
added dropwise via cannula. After completion of the addition, the 
reaction mixture was allowed to warm to room temperature and stirred for 
6 h, after which time it was quenched with saturated NH4Cl and the 
whole mixture was extracted with EtOAc (10 mL x 3). The combined 
organic layers were washed with water (10 mL) and brine (10 mL), and 
dried over anhydrous MgSO4. Filtration was concentrated in vacuo, and 
the residue was purified by column chromatography (silica gel, 10% 
EtOAc in hexane) to provide 11 (163 mg, 86%) as a white solid. 
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